Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications.

Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood ...

Nonalcoholic steatohepatitis (NASH) is a more severe type of nonalcoholic fatty liver disease (NAFLD) that can damage your liver. It can cause liver scarring and other potentially serious ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Study found that higher soft drink consumption is associated with an increased risk of nonalcoholic fatty liver disease, ...

Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...

Doctors at the four hospitals—Ochsner Health, Tulane Medical Center, Mayo Clinic, and USC Keck—who evaluated me for a liver ...

Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- (NYSE ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the ...